Ceftolozane-tazobactam pharmacokinetics in a critically ill patient on continuous venovenous hemofiltration

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 3, 2016, Pages 1899-1901

  Oliver, Wesley D ^a   Heil, Emily L ^a   Gonzales, Jeffrey P ^b   Mehrotr, Shailly ^a,b   Robinett, Kathryn ^c   Salee, Paul ^b,c   Nicolau, David P ^d  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTOLOZANE PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; CEFTOLOZANE; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID; TAZOBACTAM;

ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; CONTINUOUS HEMOFILTRATION; CRITICALLY ILL PATIENT; DRUG HALF LIFE; HUMAN; MAXIMUM PLASMA CONCENTRATION; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; TIME TO MAXIMUM PLASMA CONCENTRATION; ANALOGS AND DERIVATIVES; CASE REPORT; CRITICAL ILLNESS; DRUG EFFECTS; HEMOFILTRATION; INTENSIVE CARE UNIT; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; PROSTHESIS-RELATED INFECTIONS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CRITICAL ILLNESS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HEMOFILTRATION; HUMANS; INTENSIVE CARE UNITS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PENICILLANIC ACID; PROSPECTIVE STUDIES; PROSTHESIS-RELATED INFECTIONS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84960158006     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02608-15     Document Type: Article

References (10)

1. Miller B, Hershberger E, Benziger D, Trinh M, Friedland I. 2012. Pharmacokinetics and safety of intravenous ceftolozane/tazobactam in healthy adult subjects following single and multiple ascending doses. Antimicrob Agents Chemother 56:3086-3091. http://dx.doi.org/10.1128/AAC.06349-11.
2. Wooley M, Miller B, Krishna G, Hershberger E, Chandorkar G. 2014. Impact of renal function on the pharmacokinetics and safety of ceftolozane/tazobactam. Antimicrob Agents Chemother 58:2249-2255. http://dx.doi.org/10.1128/AAC.02151-13.
3. Cubist Pharmaceuticals, Inc. 2014. Zerbaxa (ceftolozane/tazobactam) for injection, for intravenous use. Package insert. Cubist Pharmaceuticals, Inc., Lexington, MA. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/206829lbl.pdf.
4. Awissi DK, Beauchamp A, Hébert E, Lavigne V, Munoz DL, Lebrun G, Savoie M, Fagnan M, Amyot J, Tétreault N, Robitaille R, Varin F, Lavallée C, Pichette V, Leblanc M. 2015. Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy. Pharmacotherapy 35: 600-607. http://dx.doi.org/10.1002/phar.1604.
5. Heil EL, Lowery AV, Thom KA, Nicolau DV. 2015. Treatment of multidrug-resistant Pseudomonas aeruginosa using extended-infusion antimicrobial regimens. Pharmacotherapy 35:54-58. http://dx.doi.org/10 .1002/phar.1514.
6. National Institute of Mental Health, University of Virginia. 2016. Safety and efficacy study of ceftolozane/tazobactam to treat ventilated nosocomial pneumoniae (ASPECT-NP). Registration no. NCT02070757. National Institutes of Health, Bethesda, MD. http://clinicaltrials.gov/show/NCT02070757.
7. Malone RS, Fish DN, Abraham E, Teitelbaum I. 2001. Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 45:3148-3155. http://dx.doi.org/10.1128/AAC.45.11.3148-3155.2001.
8. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1-12. http://dx.doi.org/10.1086/516284.
9. Tam VH, McKinnon PS, Akins RL, Rybak MJ, Drusano GL. 2002. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother 50:425-428. http://dx.doi.org/10.1093/jac/dkf130.
10. McKinnon PS, Paladino JA, Schentag JJ. 2008. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T-MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 31:345-351. http://dx.doi.org/10.1016/j.ijantimicag.2007.12.009.